FourThought Financial Partners LLC Boosts Stake in Insulet Co. (NASDAQ:PODD)

FourThought Financial Partners LLC boosted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,461 shares of the medical instruments supplier’s stock after acquiring an additional 61 shares during the period. FourThought Financial Partners LLC’s holdings in Insulet were worth $968,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PODD. Qube Research & Technologies Ltd grew its holdings in Insulet by 227.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after buying an additional 268,553 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Insulet by 119.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock worth $17,223,000 after purchasing an additional 43,147 shares during the period. Asset Management One Co. Ltd. boosted its holdings in Insulet by 33.7% in the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after purchasing an additional 9,240 shares during the last quarter. Graham Capital Management L.P. increased its holdings in shares of Insulet by 689.8% during the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock worth $3,683,000 after buying an additional 20,171 shares during the last quarter. Finally, Aquila Investment Management LLC acquired a new stake in shares of Insulet during the 4th quarter worth approximately $1,302,000.

Analysts Set New Price Targets

PODD has been the subject of several analyst reports. Barclays lowered their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Piper Sandler cut their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. JPMorgan Chase & Co. upped their target price on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Finally, Stifel Nicolaus lifted their price target on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $243.21.

Insulet Stock Up 0.6 %

Shares of NASDAQ:PODD traded up $1.01 during trading on Friday, hitting $174.43. The company’s stock had a trading volume of 614,615 shares, compared to its average volume of 712,105. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The business has a 50 day moving average price of $169.57 and a two-hundred day moving average price of $180.95. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The company has a market capitalization of $12.21 billion, a PE ratio of 59.94, a P/E/G ratio of 3.14 and a beta of 1.00.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping the consensus estimate of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. Insulet’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. As a group, research analysts expect that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.